The Drugs Controller General of India (DCGI) granted Emergency Use Authorisation (EAU) to Zydus Cadila’s three-dose Covid-19 vaccine ZyCoV-D on Friday. It is also the first approved vaccine against Covid-19 in India which can be administered to everyone above the age of 12.
ZyCoV-D is a vaccine which has been developed in partnership with the government’s Department of Biotechnology.
Here’s all you need to know about the Zydus Cadila’s ZyCoV-D vaccine:
- Zydus Cadila’s ZyCoV-D is the first ever Covid-19 vaccine to receive approval for kids above the age of 12.
- The ZyCoV-D is also the first Covid-19 vaccine in India which will be applied using a needle-free injector.
3. This is also the world’s first DNA-based Covid-19 vaccine. The vaccine injects genetically engineered plasmids which trigger the immune system of the body to start generating spike protein against Covid-19. In addition, the plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.
4. There is set to be around 216 crore vaccines doses available for everyone in India between August to December. Of these, Health Minister Mansukh Mandaviya had stated that Zydus Cadila will be providing five crore doses. Zydus Cadila in an official release also revealed its plan to manufacture 10-12 crore vaccine doses of ZyCoV-D annually.
5. This is the sixth COVID-19 vaccine to get the emergency use authorisation in India after Bharat Biotech’s Covaxin, Serum Institute of India’s Covishield, Russia’s Sputnik V vaccine and the vaccines of Moderna and Johnson and Johnson. Out of these, only Covaxin, Sputnik V and Covishield are available and currently in use.
6. ZycoV-D completed the Phase I, II and Phase III clinical trials which have been monitored by an independent Data Safety Monitoring Board (DSMB). The above-mentioned trial was conducted on 28,000 individuals, out of which 1,000 were children in 12-18 years age group. The clinical trial results showed 66 per cent efficacy.
According to the trial data, 67 per cent of the individuals did not test COVID positive after taking the jab, compared to those who were not inoculated.